Literature DB >> 23665777

HIV-1 outcompetes HIV-2 in dually infected Senegalese individuals with low CD4⁺ cell counts.

Dana N Raugi1, Geoffrey S Gottlieb, Papa S Sow, Macoumba Toure, Fatima Sall, Awa Gaye, Ibra N'doye, Nancy B Kiviat, Stephen E Hawes.   

Abstract

OBJECTIVE: Dual infection with HIV-1 and HIV-2, which is not uncommon in West Africa, has implications for transmission, progression, and antiretroviral therapy (ART). Few studies have examined viral dynamics in this setting. Our objective was to directly compare HIV-1 and HIV-2 viral loads and to examine whether this relationship is associated with CD4⁺ cell count. STUDY
DESIGN: This is a retrospective analysis of data from observational cohort studies.
METHODS: We compared HIV-1 and HIV-2 viral loads from 65 dually infected, ART-naive Senegalese individuals. Participants provided blood, oral fluid, and cervicovaginal lavage (CVL) or semen samples for virologic and immunologic testing. We assessed relationships between HIV-1 and HIV-2 levels using linear regression with generalized estimating equations to account for multiple study visits.
RESULTS: After adjusting for CD4⁺ cell count, age, sex, and commercial sex work, HIV-1 RNA levels were significantly higher than HIV-2 levels in semen, CVL, and oral fluids. Despite similar peripheral blood mononuclear cell DNA levels among individuals with CD4⁺ cell counts above 500 cells/μl, individuals with CD4⁺ cell counts below 500 cells/μl had higher HIV-1 and lower HIV-2 DNA levels. Individuals with high CD4⁺ cell counts had higher mean HIV-1 plasma RNA viral loads than HIV-2, with HIV-1 levels significantly higher and HIV-2 levels trending toward lower mean viral loads among individuals with low CD4⁺ cell counts.
CONCLUSION: Our data are consistent with the hypothesis that with disease progression, HIV-1 outcompetes HIV-2 in dually infected individuals. This finding helps explain differences in prevalence and outcomes between HIV-1, HIV-2, and HIV-dual infection.
© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23665777      PMCID: PMC4043222          DOI: 10.1097/QAD.0b013e328362e856

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  39 in total

1.  Inhibition of HIV type 1 replication by simultaneous infection of peripheral blood lymphocytes with human immunodeficiency virus types 1 and 2.

Authors:  K Dern; H Rübsamen-Waigmann; R E Unger
Journal:  AIDS Res Hum Retroviruses       Date:  2001-03-01       Impact factor: 2.205

2.  Possible protective effect of HIV-2 against incident HIV-1 infection: review of available epidemiological and in vitro data.

Authors:  A E Greenberg
Journal:  AIDS       Date:  2001-11-23       Impact factor: 4.177

3.  Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa.

Authors:  Geoffrey S Gottlieb; Papa Salif Sow; Stephen E Hawes; Ibra Ndoye; Mary Redman; Awa M Coll-Seck; Mame A Faye-Niang; Aissatou Diop; Jane M Kuypers; Cathy W Critchlow; Richard Respess; James I Mullins; Nancy B Kiviat
Journal:  J Infect Dis       Date:  2002-03-19       Impact factor: 5.226

4.  Dual infection with human immunodeficiency virus type 1 and type 2: impact on HIV type 1 viral load and immune activation markers in HIV-seropositive female sex workers in Abidjan, Ivory Coast.

Authors:  J N Nkengasong; L Kestens; P D Ghys; S Koblavi-Dème; R A Otten; C Bilé; C Maurice; M Kalou; M Laga; S Z Wiktor; A E Greenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2000-09-20       Impact factor: 2.205

5.  Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort.

Authors:  Sophie Matheron; Sophie Pueyo; Florence Damond; François Simon; Annie Leprêtre; Pauline Campa; Roger Salamon; Genevieve Chêne; Françoise Brun-Vezinet
Journal:  AIDS       Date:  2003-12-05       Impact factor: 4.177

6.  Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.

Authors:  Christiane A Adjé-Touré; Rachanee Cheingsong; J Gerardo Garcìa-Lerma; Serge Eholié; Marie-Yolande Borget; Jean-Marc Bouchez; Ron A Otten; Chantal Maurice; Madeleine Sassan-Morokro; René E Ekpini; Monica Nolan; Terence Chorba; Walid Heneine; John N Nkengasong
Journal:  AIDS       Date:  2003-07       Impact factor: 4.177

7.  Differences in HIV-2 plasma viral load and immune activation in HIV-1 and HIV-2 dually infected persons and those infected with HIV-2 only in Abidjan, Côte D'Ivoire.

Authors:  Stéphania Koblavi-Dème; Luc Kestens; Debra Hanson; Ronald A Otten; Marie-Yolande Borget; Célestin Bilé; Stefan Z Wiktor; Thierry H Roels; Terence Chorba; John N Nkengasong
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

8.  Trends of HIV-1, HIV-2 and dual infection in women attending outpatient clinics in Senegal, 1990-2009.

Authors:  K Heitzinger; P S Sow; N M Dia Badiane; G S Gottlieb; I N'Doye; M Toure; N B Kiviat; S E Hawes
Journal:  Int J STD AIDS       Date:  2012-10       Impact factor: 1.359

9.  Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients.

Authors:  Abraham S Alabi; Shabbar Jaffar; Koya Ariyoshi; Tom Blanchard; Maarten Schim van der Loeff; Akum Aveika Awasana; Tumani Corrah; Sehu Sabally; Ramu Sarge-Njie; Fatim Cham-Jallow; Assan Jaye; Neil Berry; Hilton Whittle
Journal:  AIDS       Date:  2003-07-04       Impact factor: 4.177

10.  Molecular epidemiology of dual HIV-1/HIV-2 seropositive adults from Senegal, West Africa.

Authors:  Geoffrey S Gottlieb; Papa Salif Sow; Stephen E Hawes; Ibra Ndoye; Awa M Coll-Seck; Marcel E Curlin; Cathy W Critchlow; Nancy B Kiviat; James I Mullins
Journal:  AIDS Res Hum Retroviruses       Date:  2003-07       Impact factor: 2.205

View more
  5 in total

1.  Detection and differentiation of HIV-2 using the point-of-care Alere q HIV-1/2 Detect nucleic acid test.

Authors:  Ming Chang; Katrin Steinmetzer; Dana N Raugi; Robert A Smith; Selly Ba; Fatima Sall; Moussa Seydi; Alassane Niang; ElHadji Ibrahima Sall; Ousseynou Cisse; Katja Rödel; Robert W Coombs; Geoffrey S Gottlieb
Journal:  J Clin Virol       Date:  2017-10-24       Impact factor: 3.168

2.  In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2.

Authors:  Robert A Smith; Dana N Raugi; Charlotte Pan; Papa Salif Sow; Moussa Seydi; James I Mullins; Geoffrey S Gottlieb
Journal:  Retrovirology       Date:  2015-02-05       Impact factor: 4.602

3.  Patients infected with CRF07_BC have significantly lower viral loads than patients with HIV-1 subtype B: mechanism and impact on disease progression.

Authors:  Szu-Wei Huang; Sheng-Fan Wang; Yu-Ting Lin; Chia-Hung Yen; Chih-Hao Lee; Wing-Wai Wong; Hung-Chin Tsai; Chia-Jui Yang; Bor-Shen Hu; Yu-Huei Lin; Chin-Tien Wang; Jaang-Jiun Wang; Zixin Hu; Daniel R Kuritzkes; Yen-Hsu Chen; Yi-Ming Arthur Chen
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

4.  Treatment outcomes and characteristics of HIV-2 patients compared to HIV-1 patients on an NNRTI-based first line art at the adult infectious diseases centre of the University Teaching Hospital (UTH) in Lusaka.

Authors:  Anita Thandiwe Bhebhe; Gershom Chongwe; Given Moonga
Journal:  Pan Afr Med J       Date:  2021-12-16

5.  Importance of an Early HIV Antibody Differentiation Immunoassay for Detection of Dual Infection with HIV-1 and HIV-2.

Authors:  Andrea Zbinden; Roland Dürig; Cyril Shah; Jürg Böni; Jörg Schüpbach
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.